Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Avacta Group Plc (AVCTF)

Avacta Group Plc (AVCTF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3650 +30.40%
on 07/01/20
1.8900 -5.82%
on 07/21/20
+0.1300 (+7.88%)
since 06/19/20

Most Recent Stories

More News
Avacta Appoints Therapeutics Chief Development Officer

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
AUTL : 15.44 (+0.46%)
Avacta Announces SARS-CoV-2 Rapid Antigen Test Clinical Collaboration

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with the Liverpool School of Tropical Medicine ("LSTM")...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta Appoints COVID-19 Rapid Antigen Test Manufacturing Partner

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that it has appointed BBI Solutions, part of BBI Group ("BBI"), to manufacture the saliva-based...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd....

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that it has begun work with the UK government's CONDOR programme to evaluate and clinically...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta Provides Update on COVID-19 Rapid Antigen Test Development Partnership With Cytiva

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta provides update on Affimer therapy for COVID-19 infection

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that collaborative work with the Centre for Virus Research at the University of Glasgow has shown...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta Provides Update on COVID-19 Antigen Diagnostic Test Development With Adeptrix

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that a BAMS(TM) diagnostic test for the COVID-19 infection, being developed with its partner...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta and Medusa19 Enter Into a Distribution Agreement For COVID-19 Antigen Test

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that it has entered into an exclusive distribution agreement with Medusa19 Limited ("Medusa19")...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Avacta Develops SARS-COV-2 Neutralising Affimer Reagents with Therapeutic Potential for COVID-19

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that several of the Affimer reagents recently generated for development of a point-of-care...

AVCTF : 1.7800 (-5.82%)
AVCT : 6.83 (-2.84%)
Trade AVCTF with:

Key Turning Points

2nd Resistance Point 1.7800
1st Resistance Point 1.7800
Last Price 1.7800
1st Support Level 1.7800
2nd Support Level 1.7800

See More

52-Week High 2.4000
Fibonacci 61.8% 2.0046
Fibonacci 50% 1.8825
Last Price 1.7800
Fibonacci 38.2% 1.7604
52-Week Low 1.3650

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar